News

News and Resources

July 30, 2024

Dr. Russel Kaufman, Renowned Medical Innovator and Business Leader, Joins Immorta Bio's Board of Directors

July 26, 2024

Immorta Bio Files Investigational New Drug Application for First in Class Senolytic Immunotherapy SenoVax™ for Treatment of Advanced Lung Cancer

June 12, 2024

Immorta Bio Reports Successful Inhibition of Lung Cancer Growth by Senolytic Immunotherapy Product SenoVax™

June 12, 2024

Senovax™: cutting-edge immunotherapy for lung cancer

May 24, 2024

Pmsc-11: pioneering liver failure treatment with stem cells

May 23, 2024

Immorta Bio Inc, a Longevity Company, Announces a Significant Breakthrough in Treatment of Liver Failure

May 7, 2024

Muscle revival: mitochondrial transplants for aging

April 23, 2024

Young mice plasma sevs: unlocking the secret to longevity

April 9, 2024

Telomir-1: the next breakthrough in anti-aging therapy

March 26, 2024

Surprising longevity boosters: top medications revealed

March 12, 2024

Patent spotlight: zip11 gene and the future of anti-aging therapies

February 27, 2024

Harvard's youth protein: turning back the aging clock

January 23, 2024

Immorta Bio Welcomes Dr. Vlad Bykoriz as its Chief Medical Officer

January 2, 2024

Immorta Bio Announces Personalized Progenitor Cell Platform for Organ Specific Regeneration

December 18, 2023

Immorta Bio Files Patent on Reversing Cellular Aging by Creation of Personalized Regenerative Cells

December 6, 2023

Venvalo Group Launches Immorta Bio, Inc Aimed at Providing Unlimited Personalized Cells for Treating Diseases of Aging and Treating Aging as Disease™

Mailing 7064 Fisher Island Drive, Miami Beach, Florida 33109

Office: 19505 Biscayne Blvd, Ste 2350 Aventura, Florida 33180

305 632-2939

info@immortabio.com

Intellectual Property